Trevi Therapeutics (TRVI) Interest & Investment Income (2018 - 2025)
Trevi Therapeutics' quarterly Interest & Investment Income came in at $1.9 million in Q4 2025, up 125.74% year-on-year from $843000.0 in Q4 2024, and down 9.42% quarter-over-quarter from $2.1 million in Q3 2025.
Trevi Therapeutics has reported Interest & Investment Income for 8 years, with the latest figure at $1.9 million in Q4 2025.
- For the quarter ending Q4 2025, Interest & Investment Income rose 125.74% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $6.3 million (up 73.63% YoY), and the FY2025 full-year result was $6.5 million, up 81.45% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $1.9 million, down from $2.1 million in the prior quarter.
- The five-year high for Interest & Investment Income was $2.1 million in Q3 2025, with the low at $2000.0 in Q2 2021.
- Average Interest & Investment Income over 5 years is $816368.4, with a median of $935000.0 recorded in 2024.
- Year-over-year, Interest & Investment Income sank 98.09% in 2021 and surged 37133.33% in 2022.
- Tracing TRVI's Interest & Investment Income over 5 years: stood at $3000.0 in 2021, then surged by 37133.33% to $1.1 million in 2022, then gained by 1.79% to $1.1 million in 2023, then retreated by 25.86% to $843000.0 in 2024, then soared by 125.74% to $1.9 million in 2025.
- The last three Interest & Investment Income figures came in at $1.9 million (Q4 2025), $2.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Dec 31, 2024 | 843,000.00 |
| Sep 30, 2024 | 826,000.00 |
| Jun 30, 2024 | 935,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.18 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.22 Mn |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 424,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Mar 31, 2022 | 4,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 4,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 14,000.00 |
| Mar 31, 2020 | 157,000.00 |
| Dec 31, 2019 | 225,000.00 |
| Sep 30, 2019 | 280,000.00 |
| Jun 30, 2019 | 229,000.00 |
| Mar 31, 2019 | 58,000.00 |
| Dec 31, 2018 | 46,000.00 |
| Sep 30, 2018 | 27,000.00 |
| Jun 30, 2018 | 38,000.00 |
| Mar 31, 2018 | 45,000.00 |